NLRP3 and lung adenocarcinoma: Combination of radiotherapy and NLRP3 agonist in wild type and anti-PD1 resistant murine-implanted lung adenocarcinoma (LUAD) models have also shown to boost immune response via activation and proliferation of T cells and thus shows improved anti-tumor effect (42) (Table 1). NLRP3 inflammasome induced by radiation can also lead to tissue damage.